CS
BIIB icon

Credit Suisse’s Biogen BIIB Stock Holding History

Credit Suisse’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,700
Closed -$648K – 3661
2021
Q4 		$648K Sell
2,700
-2,000
-43% -$514K ﹤0.01% 3640
2021
Q3 		$1.33M Sell
4,700
-300
-6% -$98.3K ﹤0.01% 3119
2021
Q2 		$1.73M Buy
5,000
+1,000
+25% +$303K ﹤0.01% 2979
2021
Q1 		$1.12M Sell
4,000
-17,900
-82% -$4.83M ﹤0.01% 3251
2020
Q4 		$5.36M Sell
21,900
-2,600
-11% -$671K ﹤0.01% 2041
2020
Q3 		$6.95M Sell
24,500
-3,500
-13% -$976K ﹤0.01% 1582
2020
Q2 		$7.49M Buy
28,000
+12,500
+81% +$3.76M 0.01% 1452
2020
Q1 		$4.9M Sell
15,500
-47,900
-76% -$14.5M ﹤0.01% 1555
2019
Q4 		$18.8M Hold
63,400
– – 0.01% 1064
2019
Q3 		$14.8M Buy
63,400
+5,900
+10% +$1.37M 0.01% 1092
2019
Q2 		$13.4M Buy
57,500
+42,200
+276% +$9.74M 0.01% 1141
2019
Q1 		$3.62M Buy
15,300
+3,100
+25% +$976K ﹤0.01% 1963
2018
Q4 		$3.67M Buy
+12,200
New +$3.89M ﹤0.01% 1809
2017
Q4 		– Sell
-20,500
Closed -$6.42M – 3984
2017
Q3 		$6.42M Sell
20,500
-64,500
-76% -$19.1M 0.01% 1570
2017
Q2 		$23.1M Buy
+85,000
New +$22.5M 0.02% 735
2017
Q1 		– Sell
-68,000
Closed -$19.3M – 3814
2016
Q4 		$19.3M Sell
68,000
-200
-0.3% -$59.3K 0.02% 833
2016
Q3 		$21.3M Buy
+68,200
New +$20.2M 0.02% 792
2015
Q3 		– Sell
-10,000
Closed -$4.04M – 4270
2015
Q2 		$4.04M Buy
+10,000
New +$4.01M ﹤0.01% 1930

Other funds holding BIIB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Credit Suisse's BIIB Position: Q1 2024 in Review

Credit Suisse reduced its Biogen (BIIB) stake by 8.4% in Q1 2024, selling an estimated $6.25M and leaving 291,725 shares worth $62.9M. The position accounts for 0.06% of the portfolio, ranked #311.

Credit Suisse first reported a position in BIIB in Q2 2013 and has held it in 44 quarters since. The position peaked at $283M in Q2 2015. 954 funds tracked by Wall St. Rank hold BIIB as of Q1 2024.

  • Credit Suisse held 291,725 shares of Biogen worth $62.9M as of Q1 2024.
  • Credit Suisse sold 26,696 Biogen shares in Q1 2024, an estimated $6.25M.
  • Biogen made up 0.06% of Credit Suisse's portfolio in Q1 2024, its #311 holding.
  • Credit Suisse first reported a position in Biogen in Q2 2013 and has held it in 44 quarters since.
  • Credit Suisse's Biogen position peaked at $283M in Q2 2015.
  • 954 funds tracked by Wall St. Rank held Biogen as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.